Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:LITS NASDAQ:ORMP NASDAQ:TNYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$2.86$2.53$1.77▼$4.94$163.88M3.34941,839 shs576,724 shsLITSLite Strategy$1.22+3.4%$1.17$0.95▼$9.00$42.91M0.25319,919 shs301,142 shsORMPOramed Pharmaceuticals$4.73+3.7%$3.70$1.98▼$5.01$184.43M1.27172,411 shs117,948 shsTNYATenaya Therapeutics$0.94-2.6%$0.77$0.36▼$2.35$208.21M2.774.80 million shs5.38 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics0.00%+5.15%+7.52%+28.83%+51.32%LITSLite Strategy+3.39%+7.02%+6.09%+8.93%+121,999,900.00%ORMPOramed Pharmaceuticals+3.73%+20.97%+24.47%+45.54%+114.03%TNYATenaya Therapeutics-2.55%+10.21%+26.52%+41.67%+141.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$2.86$2.53$1.77▼$4.94$163.88M3.34941,839 shs576,724 shsLITSLite Strategy$1.22+3.4%$1.17$0.95▼$9.00$42.91M0.25319,919 shs301,142 shsORMPOramed Pharmaceuticals$4.73+3.7%$3.70$1.98▼$5.01$184.43M1.27172,411 shs117,948 shsTNYATenaya Therapeutics$0.94-2.6%$0.77$0.36▼$2.35$208.21M2.774.80 million shs5.38 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics0.00%+5.15%+7.52%+28.83%+51.32%LITSLite Strategy+3.39%+7.02%+6.09%+8.93%+121,999,900.00%ORMPOramed Pharmaceuticals+3.73%+20.97%+24.47%+45.54%+114.03%TNYATenaya Therapeutics-2.55%+10.21%+26.52%+41.67%+141.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 2.70Moderate Buy$10.00249.65% UpsideLITSLite Strategy 1.00SellN/AN/AORMPOramed Pharmaceuticals 2.00HoldN/AN/ATNYATenaya Therapeutics 2.86Moderate Buy$4.00327.81% UpsideCurrent Analyst Ratings BreakdownLatest LITS, ORMP, TNYA, and BDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/29/2026BDTXBlack Diamond Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.004/23/2026BDTXBlack Diamond Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)3/27/2026ORMPOramed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)3/17/2026BDTXBlack Diamond Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$13.00 ➝ $14.003/12/2026TNYATenaya Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$2.003/12/2026TNYATenaya Therapeutics William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform3/12/2026TNYATenaya Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.003/5/2026TNYATenaya Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond Therapeutics$70M2.34$0.53 per share5.42$1.82 per share1.57LITSLite Strategy$65.30M0.68$6.10 per share0.20$4.96 per share0.25ORMPOramed Pharmaceuticals$2M95.66$0.09 per share50.26$5.02 per share0.94TNYATenaya TherapeuticsN/AN/AN/AN/A$0.49 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics$22.37M-$0.77N/AN/AN/AN/A-30.18%-23.91%N/ALITSLite Strategy-$15.94M-$1.33N/AN/AN/AN/A-86.45%-85.04%N/AORMPOramed Pharmaceuticals$64.05M$1.493.17N/AN/AN/A-6.83%-6.25%N/ATNYATenaya Therapeutics-$90.60M-$0.47N/AN/AN/AN/A-80.56%-65.21%N/ALatest LITS, ORMP, TNYA, and BDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q3 2026LITSLite StrategyN/A-$0.66N/A-$0.66N/AN/A5/7/2026Q1 2026BDTXBlack Diamond Therapeutics-$0.18-$0.16+$0.02-$0.16$25.00 millionN/A5/6/2026Q1 2026TNYATenaya Therapeutics-$0.09-$0.09N/A-$0.09$7.50 million$0.23 million3/27/2026Q4 2025ORMPOramed Pharmaceuticals-$0.08-$0.06+$0.02$0.24$0.50 millionN/A3/16/2026Q4 2025BDTXBlack Diamond Therapeutics-$0.18-$0.14+$0.04-$0.27$9.38 millionN/A3/11/2026Q4 2025TNYATenaya Therapeutics-$0.12-$0.12N/A-$0.12N/AN/A2/17/2026Q2 2026LITSLite StrategyN/A-$0.82N/A-$0.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/ALITSLite StrategyN/AN/AN/AN/AN/AORMPOramed Pharmaceuticals$0.255.29%N/A16.78%N/ATNYATenaya TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.468.46LITSLite StrategyN/A10.0410.04ORMPOramed PharmaceuticalsN/A6.986.98TNYATenaya TherapeuticsN/A5.755.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%LITSLite Strategy52.38%ORMPOramed Pharmaceuticals12.73%TNYATenaya Therapeutics90.54%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics9.29%LITSLite Strategy1.60%ORMPOramed Pharmaceuticals17.80%TNYATenaya Therapeutics48.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9057.30 million51.98 millionOptionableLITSLite Strategy10036.36 million35.78 millionN/AORMPOramed Pharmaceuticals1040.45 million33.25 millionOptionableTNYATenaya Therapeutics110217.00 million111.43 millionOptionableLITS, ORMP, TNYA, and BDTX HeadlinesRecent News About These CompaniesTenaya Therapeutics Reports Significant Reductions in Premature Ventricular Contractions in Interim Results from TN-401 Gene Therapy Clinical Trial39 minutes ago | quiverquant.comQPositive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC1 hour ago | globenewswire.comTenaya Therapeutics (TNYA) Is Up 26.6% After TN-401 Data Buzz and Narrower Losses Has The Bull Case Changed?May 12 at 2:01 PM | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Context Therapeutics (CNTX)May 11, 2026 | theglobeandmail.comTenaya Therapeutics (NASDAQ:TNYA) Upgraded by Wall Street Zen to "Hold" RatingMay 9, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Tenaya Therapeutics (TNYA)May 7, 2026 | theglobeandmail.comTenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue EstimatesMay 6, 2026 | zacks.comTenaya Therapeutics (NASDAQ:TNYA) Posts Earnings Results, Hits EstimatesMay 6, 2026 | marketbeat.comTenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 6, 2026 | globenewswire.comTenaya Therapeutics (TNYA) Projected to Post Quarterly Earnings on WednesdayMay 6, 2026 | marketbeat.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 3, 2026 | marketbeat.comTenaya Therapeutics (NASDAQ:TNYA) Stock Price Down 4.4% - Here's WhyApril 30, 2026 | marketbeat.comTenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2 ...April 27, 2026 | finance.yahoo.comTenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026April 27, 2026 | globenewswire.comTenaya Therapeutics (TNYA) price target increased by 11.11% to 10.20March 27, 2026 | msn.comWilliam Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product PipelineMarch 24, 2026 | insidermonkey.comTenaya Therapeutics, Inc. (TNYA) reports Q4 EPS of (12c), in line with consensusMarch 20, 2026 | msn.comTenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam DealMarch 13, 2026 | finance.yahoo.comTenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 11, 2026 | globenewswire.comTenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular DystrophyMarch 9, 2026 | finance.yahoo.comTenaya Therapeutics Reports TN-301 Outperforms Givinostat in Enhancing Muscle Function and Addressing DMD CardiomyopathyMarch 9, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLITS, ORMP, TNYA, and BDTX Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$2.86 0.00 (0.00%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$2.85 -0.01 (-0.31%) As of 07:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Lite Strategy NASDAQ:LITS$1.22 +0.04 (+3.39%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$1.22 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Oramed Pharmaceuticals NASDAQ:ORMP$4.73 +0.17 (+3.73%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$4.68 -0.05 (-1.08%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.Tenaya Therapeutics NASDAQ:TNYA$0.94 -0.02 (-2.55%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$0.96 +0.03 (+3.10%) As of 07:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
